FDA Grants ODD to AP303 for Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease
The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.
Source: pharmacytimes.com